Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo

@inproceedings{Poole2014HealthUO,
  title={Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo},
  author={Chris D. Poole and Mark P Connolly and Jane Chang and Craig J Currie},
  booktitle={Gastric Cancer},
  year={2014}
}
In this analysis we report patients with advanced gastrointestinal stromal tumors (GIST) refractory to imatinib and sunitinib therapy as derived from the EuroQol-5D (EQ-5D) for progression-free (PF) and progressive disease health status. Data were analyzed from a phase III trial conducted at 57 hospitals in 17 countries (trial registration number, NCT01271712). Patients with advanced GIST were randomized (2:1) to receive blinded treatment using oral regorafenib 160 mg daily or placebo, plus… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 22 references

EuroQoL Group; 2011

R Rabin, M Oemar, . RotterdamOppeM.EQ-5D-3LUserGuide
http://www.euroqol.org/ fileadmin/user_upload/Documenten/PDF/Folders_Flyers/User Guide_EQ-5D-3L.pdf • 2013
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…